BL LATANOPROST SOLUTION

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

LATANOPROST

Tersedia dari:

BAUSCH & LOMB INC

Kode ATC:

S01EE01

INN (Nama Internasional):

LATANOPROST

Dosis:

50MCG

Bentuk farmasi:

SOLUTION

Komposisi:

LATANOPROST 50MCG

Rute administrasi :

OPHTHALMIC

Unit dalam paket:

2.5ML

Jenis Resep:

Prescription

Area terapi:

PROSTAGLANDIN ANALOGS

Ringkasan produk:

Active ingredient group (AIG) number: 0132916002; AHFS:

Status otorisasi:

APPROVED

Tanggal Otorisasi:

2013-04-02

Karakteristik produk

PRODUCT MONOGRAPH
PR
BL LATANOPROST
Latanoprost Ophthalmic Solution
50 mcg/mL
PROSTAGLANDIN F2Α ANALOGUE
BAUSCH & LOMB INCORPORATED DATE OF REVISION:
1400 North Goodman Street
June 30, 2022
Rochester NY, USA
14609
Imported and Distributed by:
BAUSCH + LOMB CORPORATION
520 Applewood Crescent
Vaughan, Ontario
L4K 4B4
Control #: 260462
_Pr_
_BL LATANOPROST Product Monograph _
_Page 2 of 28_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY
PRODUCT
INFORMATION..............................................................................
3
INDICATIONS
AND
CLINICAL
USE
...................................................................................
3
CONTRAINDICATIONS.......................................................................................................
3
WARNINGS
AND
PRECAUTIONS
......................................................................................
4
ADVERSE
REACTIONS
.......................................................................................................
6
DRUG
INTERACTIONS
.......................................................................................................
7
DOSAGE
AND
ADMINISTRATION
.....................................................................................
7
OVERDOSAGE.....................................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY
.................................................................... 9
STORAGE
AND
STABILITY
...............................................................................................10
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING .....................................................10
PART II: SCIENTIFIC INFORMATION
.............................................................................
11
PHARMACEUTICAL
INFORMATION................................................................................11
CLINICAL
TRIALS
.........................